Nectar Lifesciences (LUX:NECLF) Total Liabilities : $135.1 Mil (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Nectar Lifesciences Total Liabilities?

Nectar Lifesciences's Total Liabilities for the quarter that ended in Mar. 2024 was $135.1 Mil.

Nectar Lifesciences's quarterly Total Liabilities declined from Sep. 2023 ($129.45 Mil) to Dec. 2023 ($0.00 Mil) but then increased from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($135.12 Mil).

Nectar Lifesciences's annual Total Liabilities declined from Mar. 2022 ($171.01 Mil) to Mar. 2023 ($136.70 Mil) and declined from Mar. 2023 ($136.70 Mil) to Mar. 2024 ($135.12 Mil).

Nectar Lifesciences Total Liabilities Historical Data

The historical data trend for Nectar Lifesciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nectar Lifesciences Total Liabilities Chart

Nectar Lifesciences Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

200.83

182.11

171.01

136.70

135.12

Nectar Lifesciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															136.70	-	129.45	-	135.12

Nectar Lifesciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Nectar Lifesciences's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	117.177	+	(16.9	+	1.046
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	135.1

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	263.915	-	128.792
	=	135.1

Nectar Lifesciences's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	117.177	+	(16.9	+	1.046
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	135.1

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	263.915	-	128.792
	=	135.1

Nectar Lifesciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of Nectar Lifesciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Nectar Lifesciences (LUX:NECLF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nectar Lifesciences Ltd (LUX:NECLF) » Definitions » Total Liabilities

Traded in Other Exchanges

NECLIFE:India 532649:India

Address

SCO 38-39, Sector 9d, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009

Website

https://www.neclife.com

Nectar Lifesciences Ltd is an India-based pharmaceutical company. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products, The company's product includes cefixime trihydrate, cefdinir, cefprozil, cefoxitin sodium, cefpirome sulphate, and others. Geographically, it derives a majority of its revenue from India.

Nectar Lifesciences (LUX:NECLF) Headlines

No Headlines